CMG Pharmaceutical Co. Ltd (058820) — Cash Flow Reinvestment Rate
CMG Pharmaceutical Co. Ltd (058820) has a Cash Flow Reinvestment Rate of 113.83x as of December 2024, reinvesting ₩33.02 Billion (capex ₩31.75 Billion plus investments ₩1.27 Billion) from operating cash flow of ₩290.09 Million. Check 058820 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
CMG Pharmaceutical Co. Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for CMG Pharmaceutical Co. Ltd across 11 annual periods. Explore 058820 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for CMG Pharmaceutical Co. Ltd (2014–2024)
Year-by-year capital reinvestment analysis for CMG Pharmaceutical Co. Ltd. For live market cap and broader valuation context, see CMG Pharmaceutical Co. Ltd market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 301.60x | ₩87.49 Billion | ₩290.09 Million | ₩31.75 Billion | ▲ +2612.3% |
| 2023 | 11.12x | ₩43.47 Billion | ₩3.91 Billion | ₩15.25 Billion | ▲ +159.3% |
| 2022 | 4.29x | ₩21.18 Billion | ₩4.94 Billion | ₩10.31 Billion | ▲ +94.2% |
| 2021 | 2.21x | ₩12.43 Billion | ₩5.63 Billion | ₩3.95 Billion | ▼ -71.3% |
| 2020 | 7.70x | ₩22.66 Billion | ₩2.94 Billion | ₩9.65 Billion | ▼ -67.6% |
| 2019 | 23.77x | ₩67.12 Billion | ₩2.82 Billion | ₩8.18 Billion | ▲ +41.5% |
| 2018 | 16.81x | ₩14.90 Billion | ₩886.78 Million | ₩2.55 Billion | ▲ +1871.7% |
| 2017 | 0.85x | ₩1.66 Billion | ₩1.95 Billion | ₩760.59 Million | ▼ -96.3% |
| 2016 | 23.34x | ₩53.90 Billion | ₩2.31 Billion | ₩799.00 Million | ▲ +551.8% |
| 2015 | 3.58x | ₩8.64 Billion | ₩2.41 Billion | ₩3.64 Billion | ▼ -72.5% |
| 2014 | 13.02x | ₩9.44 Billion | ₩724.89 Million | ₩9.42 Billion | — |